A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

Alnylam Pharmaceuticals, Inc.0 个研究点目标入组 25 人开始时间: 2014年10月3日最近更新: 2019年2月28日

试验速览

暂无简介。

•1. Previously received and tolerated ALN-TTRSC in Study ALN-TTRSC-002; and completed Study ALN-TTRSC-002 through the Day 90 visit
•2. Adequate liver function, demonstrated by an aspartate transaminase and alanine transaminase = 2.5 × the upper limit of normal, total bilirubin< 2 g/dL (34.2 µmol/L), and albumin > 3 g/dL (> 4.35 µmol/L)
•3. Women of child-bearing potential (WOCBP) must have a negative pregnancy test, cannot be breast feeding, and must be willing to use a highly effective method of contraception prior to Screening/Baseline, throughout study participation, and for 1 month after last dose administration
•4. Males who agree to use appropriate means of contraception throughout study participation until 1 month after last dose administration
•5. Patient, or patient’s legal representative, is able and willing to provide written informed consent and the patient is willing to comply with the study requirements.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 3
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 22

•1. Estimated Glomerular Filtration Rate < 20 mL/min/1.73m2 (using the Modification of Diet in Renal Disease [MDRD] formula)
•2. Uncontrolled hypertension
•3. Uncontrolled ischemic heart disease
•4. Uncontrolled clinically significant cardiac arrhythmia
•5. Untreated hypo- or hyperthyroidism
•6. Prior major organ transplant
•7. Known or suspected systemic bacterial, viral, parasitic, or fungal infection
•8. Seropositive for hepatitis B virus, hepatitis C virus (HCV) or known to be human immunodeficiency virus positive
•9. Received an investigational agent other than tafamidis, diflunisal, doxycycline, or tauroursodeoxycholic acid, or an investigational device within 30 days prior to first dose of study drug
•10. Discontinued ALN-TTRSC-002 study due to a treatment-related AE
•11. Metastatic cancer within the past 5 years
•12. Any conditions which, in the opinion of the Investigator, would make the patient unsuitable for enrollment or could interfere with the patient’s participation in, or completion of, the study
•13. History of allergic reaction to an oligonucleotide or GalNAc

发起方